- GM Removes CEO Henderson; Whitacre is Interim Chief
- Who Were the Biggest Winners And Losers This Year?
- Look Ahead: Markets Count Down to US Jobs Report
- GE, Comcast Complete Deal Over NBC Universal: Source
- US May Raise Rates Before Jobs Recover: Fed's Plosser
- Cramer: Watch Tech Stocks Wednesday
- Stocks Likely Don't Need Santa to Keep Rally Going
- Super Fantasy Christmas Gifts of 2009
- Larry Kudlow's Open Letter to Tiger Woods
- Unemployment to Peak at 10.5%: Moody's Economist
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Predictions 2010: Technology
Text Size 
GlaxoSmithKline said it had agreed to buy biotechnology company Sirtris Pharmaceuticals for $720 million in cash, in hopes its medicines that modulate an aging-related family of enzymes will be effective against a wide range of diseases.
Glaxo said it will commence a cash tender offer for all outstanding shares of Sirtris [SIRT
Loading...
()
], at $22.50 per share.
That reflects a 84 percent premium to their closing price of $12.23 Tuesday.
"Through the acquisition of Sirtris, GlaxoSmithKline will significantly enhance its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that are believed to be involved in the aging process," the companies said in a joint release.
The companies said Sirtris has initially been exploring whether, by activating the enzymes, its experimental drugs can effectively treat Type 2 diabetes -- the most common form of diabetes which is highly linked to obesity and generally develops in adulthood.
Glaxo said it plans to retain all Sirtris employees, which will continue to operate in Cambridge, Massachusetts as an independent unit.
"Modulation of this family of enzymes is a potentially transformative science that could address diseases associated with metabolism and aging such as diabetes, muscle wasting, and neurodegeneration," Moncef Slaoui, Glaxo's research chief, said in the release.
Print
Email
- Will the Fed raise rates? Will the dollar continue its slide? CNBC experts weigh in on the year ahead.
- Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
- Do you have what it takes to run your own business? Ask yourself these questions.
- Heavily armed pirates in Somalia have set up a sort of stock exhange to fund their hijackings.
- Since its launch in 1998, Google has become a primary force on the Internet. How much do you know about the company?
- A famed author has written all his work on an old typewriter that is now up for auction. The NYT reports.
Data is a real-time snapshot *Data is delayed at least 15 minutes